TRINETRA › Sectors › Healthcare
Sun Pharmaceutical Industries Limited (SUNPHARMA) — share price, P/E and fundamentals
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) closed at ₹1,777.70 on 30 Oct 2026, +5.9% over one year, against a 52-week range of ₹1,583.70 – ₹2,046.90.
In the quarter ended 30 Sept 2026 (consolidated, filed 30 Oct 2026) it reported revenue of ₹16,199 cr and net profit of ₹1,989 cr, a 12.3% net margin; revenue grew 11.9% and profit fell 24.2% year on year.
On four consecutive filed quarters its trailing P/E is 38.9; since 22 May 2025 its own P/E has ranged from 34.3 to 41.9 (median 37.4), and today's reading is higher than 76% of those 356 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 8.9%, ROCE 14.2%, debt-to-equity 0.03, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 48% of 63 sector peers; PBT margin higher than 56% of 63 sector peers; ROE higher than 19% of 63 sector peers.
Key figures
| Last close | ₹1,777.70 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -3.9% / +9.7% / +5.9% |
| 52-week low – high | ₹1,583.70 – ₹2,046.90 |
| Market capitalisation | ₹4,26,524 cr |
| Trailing P/E | 38.9 |
| Price / book | 4.78 |
| EV / EBITDA | 22.4 |
| Earnings yield | 2.6% |
| TTM EPS | ₹45.71 |
| TTM net profit | ₹10,966 cr |
| Quarter revenue | ₹16,199 cr |
| Quarter net profit | ₹1,989 cr |
| Net margin | 12.3% |
| Revenue growth (YoY) | +11.9% |
| Profit growth (YoY) | -24.2% |
| Return on equity | 8.9% |
| ROCE | 14.2% |
| Debt / equity | 0.03 |
| Current ratio | 2.94 |
| Free cash flow | ₹1,356 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹262.1 cr |
Against Healthcare peers
| Metric | SUNPHARMA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.28 | 12.67 | 48 |
| PBT margin | 19.50 | 17.57 | 56 |
| ROE | 8.91 | 13.87 | 19 |
| ROCE | 14.18 | 16.59 | 35 |
| Debt / equity | 0.03 | 0.11 | 38 |
| FCF margin | 4.31 | -0.87 | 60 |
| Cash conversion | 0.64 | 1.25 | 15 |
| Trailing P/E | 38.89 | 43.26 | 39 |
Questions
What is the P/E ratio of Sun Pharmaceutical Industries Limited?
Sun Pharmaceutical Industries Limited's trailing P/E is 38.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 22 May 2025 its P/E has ranged 34.3–41.9.
What were Sun Pharmaceutical Industries Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Sun Pharmaceutical Industries Limited reported revenue of ₹16,199 cr and net profit of ₹1,989 cr (consolidated), filed with the exchange on 30 Oct 2026.
What is Sun Pharmaceutical Industries Limited's ROE?
Return on equity is 8.9% based on the balance sheet dated 30 Sept 2026.
Does Sun Pharmaceutical Industries Limited have debt?
Debt-to-equity is 0.03 on the balance sheet dated 30 Sept 2026.
What is SUNPHARMA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SUNPHARMA traded between ₹1,583.70 and ₹2,046.90.
Other Healthcare stocks
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.